Company Overview and News

Pfenex Announces Pricing of Offering of 6,800,000 Shares of Common Stock

2018-05-23 globenewswire
SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced the pricing of an underwritten public offering of 6,800,000 shares of its common stock at a price of $5.50 per share pursuant to its existing shelf registration statement.

Pfenex Announces Offering of Common Stock

2018-05-22 globenewswire
SAN DIEGO, May 22, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American:PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Pfenex expects to grant the underwriters a 30-day option to purchase additional shares of its common stock.

Pfenex: A Buy For Their Therapeutic Proteins Platform

2018-05-18 seekingalpha
On May 14, Pfenex announced positive topline results from a phase 3 trial which showed their lead candidate, PF708-301 had comparable overall profiles with Eli Lilly's Forteo in osteoporosis.

FDA Calls Out Pharma Companies for Blocking Requests for Samples from Generic Manufacturers

2018-05-17 biospace
In order to drive the manufacture of affordable generic drugs, the U.S.Food and Drug Administration is naming names of companies that have attempted to block competition.

Pfenex's (PFNX) CEO Evert Schimmelpennink on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Greetings, ladies and gentlemen, and welcome to the Pfenex First Quarter 2018 Results and Business Update call. [Operator Instructions] As a reminder, this conference is being recorded.

Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Poten...

2018-05-11 biospace
Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney's Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.

Alpine: Elucidating The Acquisition Prospects Of A Young Sleeping Giant

2018-05-11 seekingalpha
Alpine is leveraging on its stellar therapeutic innovation platforms (TIP and vIgD) to deliver the next-generation immuno-oncology (I-O) therapeutics.

How Did Jazz Pharmaceuticals Perform in 1Q18?

2018-05-10 marketrealist
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.

4 Specialty Pharma Stocks That Deutsche Bank Likes for the Rest of 2018

2018-05-10 247wallst
While large cap pharmaceutical stocks have had a very solid year despite the rumbling by the administration over drug pricing, many smaller specialty pharmaceuticals have lagged. Despite that underperformance, some outstanding earnings and, in some cases, even better forward guidance could make some of these companies a best play for the rest of the year.

Your Daily Pharma Scoop: AcelRx Resubmits, MannKind Finds New Realms, VTVT Up On Mixed Data

2018-05-10 seekingalpha
If you recall your AcelRx (NASDAQ:ACRX), it got a CRL for DSUVIA lasy year citing safety concerns and drug administration issues. The exact things the FDA said, as reported by the company, were: “The two primary recommendations within the CRL are: first, while the safety database was suitable in number of patients, the collection of additional data was requested on at least 50 patients to assess the safety of DSUVIA dosed at the maximum amount described in the proposed labeling; second, to ensure proper administration of the tablet with the single-dose applicator, the FDA recommended certain changes to the Directions for Use to address use-related errors, including dropped tablets, to be validated through a human factors study.

Jazz Pharmaceuticals (JAZZ) Q1 Earnings, Sales Top Estimates

2018-05-09 zacks
Jazz Pharmaceuticals plc (JAZZ - Free Report) reported adjusted earnings of $2.98 per share for first-quarter 2018, which beat the Zacks Consensus Estimate of $2.76. Earnings rose 29% from the year-ago figure.

JAZZ / Jazz Pharmaceuticals, Inc. FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on May 8, 2018 Registration No. 333-

Jazz Pharmaceuticals Plc (JAZZ) Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Welcome to the Jazz Pharmaceuticals plc First Quarter 2018 Earnings Conference Call. Following an introduction from the company, we will open the call to questions.

Jazz Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-09 seekingalpha
The following slide deck was published by Jazz Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings call.

Jazz Pharmaceuticals to settle US probe for US$57 million

2018-05-09 channelnewsasia
BOSTON: Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay US$57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: G50871105